BioNTech Completes Phase II Trial of its COVID-19 Vaccine in China

By: News Team

Published on:

German vaccine maker BioNTech (NASDAQ: BNTX ) completed a phase II clinical trial of its COVID-19 vaccine in China in January, but has not yet published its results, a data record showed on Tuesday. this type of test.

The vaccine, based on messenger RNA (mRNA) technology, is one of the most widely used worldwide against COVID-19, but it has not yet received approval in China, which has only relied on the vaccine developed in the country.

China’s top medical experts have urged authorities to maintain tough measures against COVID-19 to buy time to increase vaccination rates and develop new treatments in the fight against the country’s largest outbreak.

The phase II trial on the safety and immunogenicity of the vaccine began at the end of 2020, according to a database managed by a body dependent on the United States National Institutes of Health.

Leave a Comment